Barclays Maintains Overweight on Sarepta Therapeutics, Raises Price Target to $226
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Gena Wang maintains an Overweight rating on Sarepta Therapeutics (NASDAQ:SRPT) and raises the price target from $185 to $226.
June 21, 2024 | 1:44 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barclays analyst Gena Wang maintains an Overweight rating on Sarepta Therapeutics and raises the price target from $185 to $226.
The raised price target and maintained Overweight rating from a reputable analyst at Barclays is likely to positively influence investor sentiment and drive short-term price appreciation for SRPT.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100